Home LiteratureArticle Details
PMID: 22187033 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

High frequency of complex TP53 mutations in CNS metastases from breast cancer.

British journal of cancer ·Vol. 106 ·No. 2 ·2012-01-17 ·Pages 397-404

Lo Nigro C, Vivenza D, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comino A, Merlano M, Quinlan PR, Syed N, Purdie CA, Thompson A, Palmieri C, Crook T

Abstract

Brain metastasis from breast cancer is usually associated with a poor prognosis and early death. Alteration of p53 may contribute to malignant progression by abrogation of apoptosis induced by oncogene activation and by acquisition of gain-of-function properties, which promote tumour aggression. Mutation in TP53 occurs at high frequency in carcinomas of the lung and gastro-intestinal tract, but is much less frequent, at 25%, in primary breast cancer. The frequency of TP53 alteration in the central nervous system (CNS) metastatic breast cancer is not known. In all, 23 cases of histologically confirmed CNS metastatic breast cancer were identified and the coding sequence of TP53 determined. TP53 was also sequenced in two control series of primary breast carcinomas from independent clinical centres. We demonstrate a strikingly high frequency of TP53 mutation in the CNS metastatic lesions with an over-representation of complex mutations (non-sense/deletions/insertions). Complex mutations occur in metastatic lesions in both triple-negative breast cancer and hormone receptor/HER2-positive cases. Analysis of paired primary carcinomas and brain metastatic lesions revealed evidence for both clonal selection and generation of new mutations (missense and complex) in progression from a primary breast carcinoma to brain metastasis. Mutation in TP53 is the most common genetic alteration reported during metastasis to the brain in breast cancer.

MeSH Terms
Base Sequence Breast Neoplasms/genetics,pathology Central Nervous System Neoplasms/genetics,secondary DNA Primers Female Genes, p53 Humans Mutation
Chemicals
DNA Primers
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Lo Nigro C
Laboratory of Cancer Genetics and Translational Oncology, Oncology Department, S Croce General Hospital, Cuneo, Italy.
Vivenza D
Monteverde M
Lattanzio L
Gojis O
Garrone O
Comino A
Merlano M
Quinlan P R
Syed N
Purdie C A
Thompson A
Palmieri C
Crook T
References (20)
20 references, click to expand
  1. p53 mutations in BRCA1-associated familial breast cancer.
    Lancet. 1997 Aug 30;350(9078):638-9 PMID: 9288052
  2. p53 mutations in matched primary and metastatic human tumors.
    Mol Carcinog. 1995 Jul;13(3):166-72 PMID: 7619219
  3. Metastatic behavior of breast cancer subtypes.
    J Clin Oncol. 2010 Jul 10;28(20):3271-7 PMID: 20498394
  4. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features.
    Oncogene. 1999 Jan 7;18(1):211-8 PMID: 9926936
  5. p53 mutation, deprivation and poor prognosis in primary breast cancer.
    Br J Cancer. 2010 Feb 16;102(4):719-26 PMID: 20104224
  6. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer.
    Cancer Cell. 2011 Jul 12;20(1):79-91 PMID: 21741598
  7. Analysis of gene expression involved in brain metastasis from breast cancer using cDNA microarray.
    Breast Cancer. 2002;9(1):26-32 PMID: 12196718
  8. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Cancer Res. 2009 Apr 15;69(8):3625-33 PMID: 19336573
  9. CNS metastasis in primary breast cancer.
    Expert Rev Anticancer Ther. 2007 Nov;7(11):1561-6 PMID: 18020924
  10. Identification of brain- and bone-specific breast cancer metastasis genes.
    Cancer Lett. 2009 Apr 18;276(2):212-20 PMID: 19114293
  11. Genome remodelling in a basal-like breast cancer metastasis and xenograft.
    Nature. 2010 Apr 15;464(7291):999-1005 PMID: 20393555
  12. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
    Cancer Res. 2009 Jan 15;69(2):663-71 PMID: 19147582
  13. Allelic deletions on chromosome-17 and mutations in the p53 gene in tumors metastatic to brain.
    Int J Oncol. 1994 Jan;4(1):37-42 PMID: 21566886
  14. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis.
    Br J Cancer. 1999 Aug;80(12):1968-73 PMID: 10471047
  15. Shaping genetic alterations in human cancer: the p53 mutation paradigm.
    Cancer Cell. 2007 Oct;12(4):303-12 PMID: 17936556
  16. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
    Clin Cancer Res. 2006 Feb 15;12(4):1157-67 PMID: 16489069
  17. Genes that mediate breast cancer metastasis to the brain.
    Nature. 2009 Jun 18;459(7249):1005-9 PMID: 19421193
  18. HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma.
    Histopathology. 2010 May;56(6):702-7 PMID: 20546335
  19. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
    Oncogene. 1999 Apr 15;18(15):2451-9 PMID: 10229196
  20. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Cancer. 2006 Aug 15;107(4):696-704 PMID: 16826579
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
1532-1827
Published
2012-01-17
Epub
2011-00-20
Pages
397-404
Language
English
Region
England
NLM ID
0370635
PMCID
PMC3261685
Subset
IM
Grants
Cancer Research UK · C20208/A8667 · United Kingdom
Department of Health · United Kingdom
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com